Parin Patel, DO
Urology · Champaign, ILNPI 1053737643
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Abbott at 38.7% of the total. 2025 is the largest year on record at $4,940, more than ten times the $52 reported in 2019.
Across 245 payments — averaging $36.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Johnson & Johnson$1K
- Endo Pharmaceuticals Inc.$404
- Ferring Pharmaceuticals Inc.$310
- Sumitomo Pharma America, Inc.$290
- AbbVie$286
- plus $3K from 31 others
Across 1 payment — averaging $8000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$8K
What the payments were for
- Consulting fees$3,43139%
- Travel & lodging$931%
- Food & beverage$5,23759%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1 | $3,431 |
| Johnson & Johnson | 65 | $1,348 |
| Endo Pharmaceuticals Inc. | 22 | $404 |
| Ferring Pharmaceuticals Inc. | 8 | $310 |
| Sumitomo Pharma America, Inc. | 13 | $290 |
| AbbVie | 14 | $286 |
| Boston Scientific | 10 | $279 |
| Pfizer | 13 | $264 |
| Astellas Pharma US Inc | 13 | $244 |
| Merck | 9 | $190 |
| Bayer | 8 | $167 |
| Teleflex LLC | 7 | $159 |
| BD | 7 | $150 |
| Endo USA, Inc. | 8 | $144 |
| Recor Medical Inc | 1 | $143 |
| Olympus America Inc. | 6 | $135 |
| Coloplast | 6 | $126 |
| Janssen Research & Development, LLC | 2 | $93 |
| Progenics Pharmaceuticals, Inc. | 4 | $87 |
| Urogen Pharma, Inc. | 2 | $70 |
| Dendreon Pharmaceuticals LLC | 2 | $68 |
| Myriad Genetic Laboratories, Inc. | 3 | $60 |
| Urovant Sciences Inc | 3 | $60 |
| Tolmar, Inc. | 3 | $59 |
| Procept Biorobotics Corporation | 2 | $43 |
| AstraZeneca | 2 | $36 |
| Immunitybio, Inc. | 1 | $31 |
| Tolmar Pharmaceuticals, Inc. | 1 | $31 |
| Convatec Inc. | 1 | $26 |
| Calyxo, Inc. | 1 | $24 |
| Palette Life Sciences, Inc. | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Koelis Inc. | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| 180 Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,871 in reported general payments places this provider in the 80th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 87 | $235,006 |
| XtandiEnzalutamide | 11 | $161,527 |
| MyrbetriqMirabegron | 98 | $80,882 |
| Tamsulosin Hcl | 1,172 | $20,112 |
| GemtesaVibegron | 14 | $10,686 |
| Finasteride | 675 | $9,600 |
| Trospium Chloride | 122 | $6,889 |
| Methenamine Hippurate | 59 | $5,324 |
| Estradiol | 34 | $2,202 |
| Solifenacin Succinate | 23 | $1,241 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,100 |
| Oxybutynin Chloride | 36 | $475 |
| Ciprofloxacin Hcl | 190 | $415 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $388 |
| Betamethasone Valerate | 15 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $290 | $245,692101 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $244 | $242,409109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 550 urology providers in Illinois.
Other urology in Champaign
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.